Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of long-term Echinaforce treatment over 4 months
2009-012297-12Phase 3Unknown
- Sponsor
- Bioforce AG
- Start
- Sep 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngitis comparing Echinaforce with Placebo (2 arms). Primary endpoint: Incidence of Adverse Drug Reactions. Status: unknown.
02
Drugs
echinacea purpurea extract
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on 2009-012297-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012297-12.